European Mantle Cell Lymphoma Network
Mantle Cell Lymphoma is characterised by an aggressive course with a median survival of about 3 years and long term survival of only about 10%. Due to the limited prognostic power of the available clinical and biochemical markers it has long been impossible to establish a reliable individual risk profile. In this context, clinicians, pathologists and molecular scientists have over the last years joined forces in a European network to evaluate innovative therapeutic strategies and investigate the molecular mechanisms of malignant transformation in MCL:
- Firstly, the network defined strict histologic diagnostic criteria.
- In a prospective randomised trial the superiority of myeloablational consolidation for progression-free survival could be demonstrated
- Finally, proliferational markers have been identified as the most important prognostic markers for MCL.
On the basis of these preliminary findings, a comprehensive scientific agenda
will accompany the latest clinical trial generation to evaluate the power of individual
predictive and prognostic markers (minimal residual disease, pharmacogenomics and
molecular markers). This translational approach is not only to guarantee a
differentiated, risk-stratified therapeutic approach but shall prepare the ground
for innovative molecular strategies such as proteasome inhibitors or the like.
There is close cooperation on the European level with the
- CLSG (M. Trneny, Prag/Czech Republic)
- EORTC Lymphoma Group (H. Kluin-Nelemans, Groningen/Netherlands)
- GELA (O. Hermine, Paris/France)
- GLSG (W. Hiddemann/Germany)
- GOELAMS (R. Gressin, Grenoble/France)
- HOVON (M. van t’Veer, Rotterdam/Netherlands)
- Israelian Study group (O. Shpilberg, Petah-Tiqva/Israel)
- Nordic Lymphoma Group (C. Geissler, Copenhagen/Denmark)
- OSHO (M. Herold, Erfurt/Germany)
- PLRG (J. Walewski, Warzawa/Poland)
- SAKK (N. Ketterer, Lausanne)
Here you find further information on Clinical
Intergroup »
More about Pathology
Panel »
More about WP-2 »